The Effect of the COVID-19 Pandemic on Frailty in Liver Transplant Candidates

Active, not recruiting

• Conditions: Sarcopenia; Frailty; COVID-19

• Registration Number: NCT05935800
• Lead Sponsor: Methodist Health System

Brief Summary

Frailty is associated with higher rates of morbidity, mortality, and failure to rescue after major surgical procedures \[1\]. Sarcopenia is degenerative loss of skeletal muscle mass and strength. It is a key component of physical frailty and is associated with poorer post-surgical outcomes due to decreased patient strength and vitality.

Detailed Description

This study seeks to examine whether the SARS-CoV-2 (COVID-19) pandemic, an ongoing global health crisis that was declared a national emergency by the US Federal Government on March 13, 2020, has exacerbated both frailty and sarcopenia in a population of liver transplant candidates.

Study Timeline

• Study Start: 2022-04-19
• Study First Submitted: 2023-07-06
• Study First Submitted QC: 2023-07-06
• Study First Posted: 2023-07-07
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-13
• Last Update Posted: 2023-11-15
• Primary Completion: 2024-04-19
• Study Completion: 2024-04-19

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 208

Inclusion Criteria

• Age 18 years and older Underwent pre-transplant frailty assessment (PFA) at MDMC

Exclusion Criteria

• Not a patient at Liver Institute at Methodist Dallas

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine the impact of the COVID-19 pandemic on the incidence of sarcopenia	2 years	To determine the impact of the COVID-19 pandemic on the incidence of sarcopenia and frailty in patients undergoing liver transplant evaluation at Methodist Dallas Medical Center
To determine the impact of the COVID-19 pandemic on the prevalence of sarcopenia	2 years	To determine the impact of the COVID-19 pandemic on the prevalence of sarcopenia and frailty in patients undergoing liver transplant evaluation at Methodist Dallas Medical Center

Secondary Outcome Measures

Name	Time	Method
Changes in number of comorbidities between pre- and during/post-pandemic periods	1 year	Changes in number of comorbidities between pre- and during/post-pandemic periods
Changes in severity of comorbidities between pre- and during/post-pandemic periods	1 year	Changes in severity of comorbidities between pre- and during/post-pandemic periods
Changes in type of comorbidities between pre- and during/post-pandemic periods	1 year	Changes in type of comorbidities between pre- and during/post-pandemic periods

Trial Locations

Locations (1)

Methodist Dallas Medical Center; 🇺🇸 Dallas, Texas, United States